Ignite Creation Date:
2025-12-24 @ 10:57 PM
Ignite Modification Date:
2026-02-25 @ 5:52 PM
Study NCT ID:
NCT05756569
Status:
RECRUITING
Last Update Posted:
2025-07-28
First Post:
2023-02-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Sponsor:
Emory University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-09-26
Start Date Type:
ACTUAL
Primary Completion Date:
2026-12-16
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-16
Completion Date Type:
ESTIMATED
First Submit Date:
2023-02-20
First Submit QC Date:
None
Study First Post Date:
2023-03-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-24
Last Update Post Date:
2025-07-28
Last Update Post Date Type:
ACTUAL